CING Stock Summary and Trading Ideas (Cingulate | NASDAQ:CING)

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Cingulate trades on the NASDAQ stock market under the symbol CING.

As of December 17, 2025, CING stock price declined to $3.82 with 100,970 million shares trading.

CING has a beta of 0.75, meaning it tends to be less sensitive to market movements. CING has a correlation of 0.06 to the broad based SPY ETF.

CING has a market cap of $25.81 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CING traded as high as $463.20 and as low as $1.80.

The top ETF exchange traded funds that CING belongs to (by Net Assets): VTI, VXF.

CING has underperformed the market in the last year with a price return of -5.2% while the SPY ETF gained +11.8%. CING has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.8% and -1.8%, respectively, while the SPY returned +2.0% and -1.5%, respectively.

CING support price is $3.71 and resistance is $4.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CING shares will trade within this expected range on the day.